---
layout: default
title: Publications
---

<center><a href="https://scholar.google.com/citations?user=SpJNsxYAAAAJ&hl=en"><img src="/images/google-scholar-icon.png" alt="https://scholar.google.com/citations?user=SpJNsxYAAAAJ&hl=en" title="https://scholar.google.com/citations?user=SpJNsxYAAAAJ&hl=en" width="50" height="50" /></a>
<a href="https://orcid.org/0000-0003-1297-6337"><img src="/images/orcid-icon.png" alt="https://orcid.org/0000-0003-1297-6337" title="https://orcid.org/0000-0003-1297-6337" width="50" height="50" /></a>
<a href="https://www.researchgate.net/profile/Brittany_Boribong"><img src="/images/researchgate-icon.png" alt="https://www.researchgate.net/profile/Brittany_Boribong" title="https://www.researchgate.net/profile/Brittany_Boribong" width="50" height="50" /></a>
</center>

<span style="font-size:1.5em">
**12.** Bartsch YC, St Dennis KJ, Kaplonek P, Kang J, Lam EC, Burns MD, Farkas EJ, Davis JP, **Boribong BP**, Edlow AG, Fasano A, Shreffler W, Zavadska D, Johnson M, Goldblatt D, Balazs AB, Yonker LM, & Alter G (2022). **SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children**. *Science Translational Medicine*, eabn9237. [https://doi.org/10.1126/scitranslmed.abn9237](https://doi.org/10.1126/scitranslmed.abn9237)
</span>
<br>
**11.** Yonker LM, Badaki-Makun O, Puneeta A, **Boribong BP**, Moraru G, Fenner B, Rincon J, Hopke A, Rogers B, Hinson J, Fasano A, Lee L, Kehoe SM, Larson SD, Chavez H, Levin S, Moldawer LL, & Irimia D (2022). **Monocyte anisocytosis increases during multisystem inflammatory syndrome in children with cardiovascular complications**. *BMC Infectious Disease*, 22(1), 1-11. [https://doi.org/10.1186/s12879-022-07526-9](https://doi.org/10.1186/s12879-022-07526-9)

**10.** Burns MD\*, **Boribong BP**\*, Bartsch YC, Loiselle ME, St. Denis KJ, Sheehan ML, Chen JW, Davis JP, Lima R, Edlow AG, Fasano A, Balazs AB, Alter G, & Yonker LM (2022). **Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children**. *Vaccines*, 10(4), 492. [https://doi.org/10.3390/vaccines10040492](https://doi.org/10.3390/vaccines10040492) \*denotes equal contribution

**9.** Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone C, Dauphin A, **Boribong BP**, Loiselle ME, Davis JP, Leonard MM, Kuri-Cervantes L, MGH COVID-19 Collection & Processing Team, Meyer NJ, Betts MR, Li JZ, Walker BD, Xu GY, Yonker LM, & Luban J (2022). **Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection**. *eLife*, 11, e74681. [https://doi.org/10.7554/eLife.74681](https://doi.org/10.7554/eLife.74681)

**8.** Yonker LM, Swank Z, Gilboa T, Senussi Y, Kenyon V, Papadakis L, **Boribong BP**, Carroll RW, Walt DR, & Fasano A (2022). **Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series**. *Critical Care Explorations*, 10, 2. [https://dx.doi.org/10.1097%2FCCE.0000000000000641](https://dx.doi.org/10.1097%2FCCE.0000000000000641)

**7.** **Boribong BP**, Puneeta A, & Yonker LM (2021). **The Heart of the Problem in Multisystem Inflammatory Syndrome in Children**. *Med*, 2, 9. [https://doi.org/10.1016/j.medj.2021.08.008](https://doi.org/10.1016/j.medj.2021.08.008)

**6.** Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, **Boribong BP**, Bartsch YC, Loiselle ME, Rivas MN, Porritt RA, Lima R, Davis JP, Farkas EJ, Burns MD, Young N, Mahajan VS, Hajizadeh S, Herrera Lopez XI, Kreuzer J, Morris R, Martinez EE, Han I, Griswold Jr. K, Barry NC, Thompson DB, Church G, Edlow AG, Haas W, Pillai S, Arditi M, Alter G, Walt DR, & Fasano A (2021). **Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier**. *The Journal of Clinical Investigation*, 131(14):e149633. [https://doi.org/10.1172/JCI149633](https://doi.org/10.1172/JCI149633)

**5.** Davis MM, Brock AM, DeHart TG, **Boribong BP**, Lee K, McClune ME, Chang Y, Cramer N, Liu J, Jones CN, & Jutras BL (2021). **The peptidoglycan-associated protein NapA plays an important role in the envelope integrity and in the pathogenesis of the lyme disease spirochete**. *PloS Pathogens*, 17, 5. [https://doi.org/10.1371/journal.ppat.1009546](https://doi.org/10.1371/journal.ppat.1009546)

**4.** Ciupe SM, **Boribong BP**, Kadelka S, & Jones CN (2021). **Bistable mathematical model of neutrophil migratory patterns after LPS-induced epigenetic reprogramming**. *Frontiers in Genetics*, 12, 172. [https://doi.org/10.3389/fgene.2021.633963](https://doi.org/10.3389/fgene.2021.633963)

**3.** **Boribong, BP**, Lenzi, MJ, Li, L, & Jones, CN (2019). **Super-low dose lipopolysaccharide dysregulates neutrophil migratory decision-making**. *Frontiers in Immunology*, 10, 359. [https://doi.org/10.3389/fimmu.2019.00359](https://doi.org/10.3389/fimmu.2019.00359)

**2.** **Boribong, BP**, Rahimi, A, & Jones, CN (2019). **Microfluidic Platform to Quantify Neutrophil Migratory Decision-Making**. In *Mouse Models of Innate Immunity* (pp. 113-122). Humana Press, New York, NY. [https://doi.org/10.1007/978-1-4939-9167-9_10](https://doi.org/10.1007/978-1-4939-9167-9_10)

**1.** Kadelka, S, **Boribong, BP**, Li, L, & Ciupe, SM (2019). **Modeling the Bistable Dynamics of the Innate Immune System**. *Bulletin of Mathematical Biology*, 81(1), 256-276. [https://doi.org/10.1007/s11538-018-0527-y](https://doi.org/10.1007/s11538-018-0527-y)
